Related Experiment Video

Updated: Apr 5, 2026

Assessing Murine Resistance Artery Function Using Pressure Myography
07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

23.4K

Pharmacogenomics of hypertension and heart disease

Meghan J Arwood1, Larisa H Cavallari, Julio D Duarte

  • 1Department of Pharmacy Practice, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL, USA, arwood@uic.edu.

Current Hypertension Reports
|August 15, 2015
PubMed

Insights

Pharmacogenetics may help personalize blood pressure medication. Genetic testing could guide treatment for hypertension and related heart conditions, but more research is needed for widespread use.

Area of Science:

  • Cardiology
  • Pharmacogenomics
  • Genetics

Background:

  • Hypertension is a major risk factor for heart disease, a leading cause of death.
  • Uncontrolled blood pressure affects over half of Americans, contributing to serious cardiovascular events.
  • Interpatient variability in drug response, due to genetic differences, complicates effective blood pressure management.

Purpose of the Study:

  • To review the pharmacogenetics of antihypertensive drug response.
  • To explore the role of pharmacogenetics in treating hypertension-related conditions like coronary artery disease and atrial fibrillation.
  • To assess the potential of pharmacogenetic testing in guiding cardiovascular treatment.

Main Methods:

  • Literature review of pharmacogenetic studies related to hypertension and cardiovascular sequelae.
  • Analysis of genetic polymorphisms influencing drug efficacy and adverse events.
  • Evaluation of current evidence for clinical implementation of pharmacogenetic testing.

Main Results:

  • Pharmacogenetic evidence is more established for treating conditions like atrial fibrillation than for direct antihypertensive response.
  • Increasing evidence suggests genetic variants can predict response to certain antihypertensive medications.
  • Significant interpatient variability in drug response highlights the need for personalized medicine approaches.

Conclusions:

  • Pharmacogenetic testing shows promise as a tool to optimize antihypertensive therapy and manage related cardiovascular diseases.
  • Further research and clinical validation are essential before pharmacogenetic guidelines can be widely adopted for hypertension treatment.
  • Personalized medicine approaches, guided by pharmacogenomics, are crucial for improving cardiovascular health outcomes.

More Related Videos

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta08:08

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta

Published on: June 10, 2015

11.9K
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
152
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
114
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
125
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
98
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69